Efficacy of the Janus Kinase 1/2 Inhibitor Ruxolitinib in the Treatment of Vasculopathy Associated with TMEM173-Activating Mutations in three children

This article demonstrates that JAK inhibition represents a highly promising and well-tolerated therapy for STING-associated vasculopathy, and which may also be relevant to the treatment of other type I interferonopathies.

from #AlexandrosSfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/2b9pJ5Q
via IFTTT